{"analyses":[{"ciLowerLimit":".548","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":".804","estimateComment":"T+OFS is the reference group for the estimation of the hazard ratio.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.664","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"87.3","upperLimit":"90.1","value":"88.8"},{"groupId":"OG001","lowerLimit":"91.6","upperLimit":"93.9","value":"92.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1328"},{"groupId":"OG001","value":"1332"}],"units":"Participants"}],"description":"Estimated percentage of patients alive and disease-free at 5 years from randomization, where breast cancer-free interval is defined as the time from randomization to the invasive breast cancer recurrence at local, regional, or distant site, or invasive contralateral breast cancer; or censored at date of last follow up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.","id":"OG000","title":"T+OFS"},{"description":"Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.","id":"OG001","title":"E+OFS"}],"paramType":"NUMBER","populationDescription":"Intention-to-treat","reportingStatus":"POSTED","timeFrame":"5-year estimate reported at a median follow-up of 72 months","title":"Breast Cancer-free Interval","type":"SECONDARY","unitOfMeasure":"percentage of participants"}